Free Trial

Stoke Therapeutics (STOK) News Today

Stoke Therapeutics logo
$9.43 +0.25 (+2.72%)
Closing price 05/28/2025 04:00 PM Eastern
Extended Trading
$9.36 -0.07 (-0.74%)
As of 05/28/2025 06:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

STOK Latest News

Stoke Therapeutics, Inc. stock logo
Toronto Dominion Bank Invests $35 Million in Stoke Therapeutics, Inc. (NASDAQ:STOK)
Toronto Dominion Bank acquired a new stake in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) during the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 3,173,258 shares of the company's stock, valued at approxi
Stoke Therapeutics, Inc. stock logo
Deutsche Bank AG Reduces Holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK)
Deutsche Bank AG decreased its holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) by 24.2% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 350,614 shares of the company's stock after selling
Stoke Therapeutics, Inc. stock logo
Toronto Dominion Bank Acquires New Position in Stoke Therapeutics, Inc. (NASDAQ:STOK)
Toronto Dominion Bank bought a new stake in Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 3,173,258 shares of the company's stoc
Stoke Therapeutics, Inc. stock logo
Tang Capital Management LLC Buys Shares of 300,000 Stoke Therapeutics, Inc. (NASDAQ:STOK)
Tang Capital Management LLC acquired a new stake in Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund acquired 300,000 shares of the company's stock, valued at approximately $3,309,000. Tang Capital
Stoke Therapeutics, Inc. stock logo
Chardan Capital Has Strong Forecast for STOK FY2025 Earnings
Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) - Investment analysts at Chardan Capital lifted their FY2025 earnings per share (EPS) estimates for shares of Stoke Therapeutics in a report issued on Wednesday, May 14th. Chardan Capital analyst R. Li now expects that the company will earn $0.
Stoke Therapeutics, Inc. stock logo
RTW Investments LP Has $56.51 Million Holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK)
RTW Investments LP increased its stake in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) by 10.1% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 5,123,525 shares of the company's stock
Analysts Issue Forecasts for STOK FY2026 Earnings
Research Analysts Issue Forecasts for STOK FY2025 Earnings
Wedbush Forecasts Stronger Earnings for Stoke Therapeutics
Q2 EPS Forecast for Stoke Therapeutics Lowered by Analyst
Stoke Therapeutics, Inc. stock logo
Stoke Therapeutics (NASDAQ:STOK) Upgraded to Strong-Buy at Cantor Fitzgerald
Cantor Fitzgerald raised shares of Stoke Therapeutics to a "strong-buy" rating in a research note on Wednesday.
Stoke Therapeutics, Inc. stock logo
MPM Bioimpact LLC Has $7.57 Million Stake in Stoke Therapeutics, Inc. (NASDAQ:STOK)
MPM Bioimpact LLC lifted its position in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) by 43.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 685,826 shares of the company's stock after
Stoke Therapeutics, Inc. stock logo
Stoke Therapeutics (NASDAQ:STOK) Shares Gap Up Following Earnings Beat
Stoke Therapeutics (NASDAQ:STOK) Shares Gap Up on Better-Than-Expected Earnings
Stoke Therapeutics, Inc. stock logo
Stoke Therapeutics, Inc. (NASDAQ:STOK) Shares Purchased by Dimensional Fund Advisors LP
Dimensional Fund Advisors LP increased its holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) by 103.4% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 538,900 shares of the company's stock after purchasing an addi
Stoke Therapeutics, Inc. stock logo
Granahan Investment Management LLC Trims Stake in Stoke Therapeutics, Inc. (NASDAQ:STOK)
Granahan Investment Management LLC cut its stake in Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) by 12.0% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 567,689 shares of the company's stock after selling 77,281
Stoke Therapeutics, Inc. stock logo
Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Consensus Rating of "Buy" from Brokerages
Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) has received a consensus rating of "Buy" from the seven brokerages that are presently covering the stock, Marketbeat reports. Six equities research analysts have rated the stock with a buy recommendation and one has assigned a strong buy re
Stoke Therapeutics, Inc. stock logo
DAFNA Capital Management LLC Has $1.89 Million Stock Position in Stoke Therapeutics, Inc. (NASDAQ:STOK)
DAFNA Capital Management LLC trimmed its holdings in shares of Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) by 17.5% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 171,097 shares of the company's stock after
Stoke Therapeutics, Inc. stock logo
Baker BROS. Advisors LP Increases Stock Position in Stoke Therapeutics, Inc. (NASDAQ:STOK)
Baker BROS. Advisors LP boosted its holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) by 6.1% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,633,838 shares of the company's stock after bu
Stoke Therapeutics, Inc. stock logo
291,795 Shares in Stoke Therapeutics, Inc. (NASDAQ:STOK) Acquired by Schonfeld Strategic Advisors LLC
Schonfeld Strategic Advisors LLC acquired a new stake in Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) during the fourth quarter, according to its most recent filing with the SEC. The firm acquired 291,795 shares of the company's stock, valued at approximately $3,218,000. Schonfeld Strategic
Stoke Therapeutics, Inc. stock logo
Stoke Therapeutics (NASDAQ:STOK) Stock Price Down 4.4% - Here's Why
Stoke Therapeutics (NASDAQ:STOK) Stock Price Down 4.4% - Time to Sell?
Stoke Therapeutics, Inc. stock logo
Stoke Therapeutics (STOK) Projected to Post Quarterly Earnings on Monday
Stoke Therapeutics (NASDAQ:STOK) will be releasing its Q1 2025 earnings before the market opens on Monday, May 5. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-5-stoke-therapeutics-inc-stock/)
Stoke Therapeutics, Inc. stock logo
Renaissance Technologies LLC Invests $1.42 Million in Stoke Therapeutics, Inc. (NASDAQ:STOK)
Renaissance Technologies LLC bought a new stake in Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 129,043 shares of the company's stock, valued at approxim
Stoke Therapeutics, Inc. stock logo
Marshall Wace LLP Sells 719,301 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK)
Marshall Wace LLP decreased its stake in Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) by 43.1% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 951,432 shares of the company's stock after selling 719
Stoke Therapeutics, Inc. stock logo
FY2029 Earnings Estimate for STOK Issued By Leerink Partnrs
Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) - Analysts at Leerink Partnrs upped their FY2029 earnings per share (EPS) estimates for Stoke Therapeutics in a research report issued on Sunday, April 13th. Leerink Partnrs analyst M. Goodman now forecasts that the company will earn $0.60 per
Stoke Therapeutics, Inc. stock logo
Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Average Rating of "Buy" by Analysts
Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) has been assigned an average rating of "Buy" from the eight brokerages that are covering the stock, Marketbeat reports. Seven research analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. T
Stoke Therapeutics, Inc. stock logo
Trexquant Investment LP Sells 58,718 Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK)
Trexquant Investment LP lowered its position in Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) by 36.3% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 103,031 shares of the company's stock after selling 58,718 shar
Stoke Therapeutics, Inc. stock logo
314,800 Shares in Stoke Therapeutics, Inc. (NASDAQ:STOK) Acquired by Norges Bank
Norges Bank bought a new position in Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm bought 314,800 shares of the company's stock, valued at approximately $3,47
Stoke Therapeutics, Inc. stock logo
Stoke Therapeutics (NASDAQ:STOK) Receives Buy Rating from Needham & Company LLC
Needham & Company LLC restated a "buy" rating and issued a $22.00 price target on shares of Stoke Therapeutics in a report on Wednesday.
Needham Keeps Their Buy Rating on Stoke Therapeutics (STOK)
Stoke Therapeutics, Inc. stock logo
What is Chardan Capital's Forecast for STOK FY2025 Earnings?
Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) - Equities researchers at Chardan Capital issued their FY2025 EPS estimates for Stoke Therapeutics in a research note issued to investors on Monday, March 24th. Chardan Capital analyst R. Li forecasts that the company will post earnings per sha
Stoke Therapeutics, Inc. stock logo
Cantor Fitzgerald Issues Positive Forecast for STOK Earnings
Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) - Equities research analysts at Cantor Fitzgerald raised their FY2025 earnings per share (EPS) estimates for Stoke Therapeutics in a report issued on Thursday, March 20th. Cantor Fitzgerald analyst C. Duncan now forecasts that the company will
Stoke Therapeutics, Inc. stock logo
What is HC Wainwright's Forecast for STOK Q3 Earnings?
Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) - Stock analysts at HC Wainwright issued their Q3 2025 EPS estimates for shares of Stoke Therapeutics in a report issued on Wednesday, March 19th. HC Wainwright analyst A. Fein forecasts that the company will post earnings per share of ($0.55)
Stoke Therapeutics, Inc. stock logo
Leerink Partnrs Weighs in on STOK Q1 Earnings
Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) - Stock analysts at Leerink Partnrs issued their Q1 2025 EPS estimates for Stoke Therapeutics in a research report issued to clients and investors on Tuesday, March 18th. Leerink Partnrs analyst M. Goodman anticipates that the company will earn
Stoke Therapeutics, Inc. stock logo
Q1 EPS Estimate for Stoke Therapeutics Lifted by Analyst
Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) - Investment analysts at Wedbush boosted their Q1 2025 earnings per share (EPS) estimates for shares of Stoke Therapeutics in a research report issued on Tuesday, March 18th. Wedbush analyst L. Chico now anticipates that the company will post e
Stoke Therapeutics, Inc. stock logo
Stoke Therapeutics, Inc. (NASDAQ:STOK) Given Consensus Recommendation of "Buy" by Brokerages
Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) have earned a consensus recommendation of "Buy" from the ten brokerages that are currently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold rating, eight have assigned a buy rat
Stoke Therapeutics, Inc. stock logo
Insider Selling: Stoke Therapeutics, Inc. (NASDAQ:STOK) General Counsel Sells 2,266 Shares of Stock
Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) General Counsel Jonathan Allan sold 2,266 shares of the firm's stock in a transaction that occurred on Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total transaction of $19,646.22. Following the completion of the sale, the general counsel now directly owns 33,510 shares of the company's stock, valued at approximately $290,531.70. This represents a 6.33 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
Stoke Therapeutics, Inc. stock logo
Insider Selling: Stoke Therapeutics, Inc. (NASDAQ:STOK) Insider Sells 3,884 Shares of Stock
Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) insider Barry Ticho sold 3,884 shares of the stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total value of $33,674.28. Following the transaction, the insider now directly owns 63,962 shares in the company, valued at approximately $554,550.54. This represents a 5.72 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
Stoke Therapeutics, Inc. stock logo
Insider Selling: Stoke Therapeutics, Inc. (NASDAQ:STOK) Director Sells 10,382 Shares of Stock
Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) Director Edward M. Md Kaye sold 10,382 shares of the stock in a transaction on Tuesday, March 18th. The shares were sold at an average price of $8.67, for a total value of $90,011.94. Following the sale, the director now owns 148,253 shares in the company, valued at $1,285,353.51. The trade was a 6.54 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link.
Stoke Therapeutics, Inc. stock logo
Equities Analysts Offer Predictions for STOK Q1 Earnings
Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) - Equities research analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for Stoke Therapeutics in a research report issued to clients and investors on Wednesday, March 19th. HC Wainwright analyst A. Fein expects that the
Stoke Therapeutics, Inc. stock logo
Stoke Therapeutics' (STOK) Buy Rating Reiterated at HC Wainwright
HC Wainwright restated a "buy" rating and issued a $47.00 target price on shares of Stoke Therapeutics in a report on Wednesday.
Stoke Therapeutics, Inc. stock logo
Stoke Therapeutics' (STOK) "Buy" Rating Reiterated at Chardan Capital
Chardan Capital reissued a "buy" rating and issued a $24.00 target price on shares of Stoke Therapeutics in a report on Wednesday.
Stoke Therapeutics, Inc. stock logo
Needham & Company LLC Reaffirms "Buy" Rating for Stoke Therapeutics (NASDAQ:STOK)
Needham & Company LLC reiterated a "buy" rating and set a $22.00 price target on shares of Stoke Therapeutics in a report on Tuesday.
Stoke Therapeutics, Inc. stock logo
Stoke Therapeutics (NASDAQ:STOK) Posts Quarterly Earnings Results, Beats Expectations By $0.38 EPS
Stoke Therapeutics (NASDAQ:STOK - Get Free Report) released its earnings results on Tuesday. The company reported ($0.18) EPS for the quarter, topping analysts' consensus estimates of ($0.56) by $0.38. Stoke Therapeutics had a negative return on equity of 54.45% and a negative net margin of 629.90%.
Stoke Therapeutics Announces CEO Transition
Get Stoke Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for STOK and its competitors with MarketBeat's FREE daily newsletter.

STOK Media Mentions By Week

STOK Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

STOK
News Sentiment

1.36

0.87

Average
Medical
News Sentiment

STOK News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

STOK Articles
This Week

3

5

STOK Articles
Average Week

Get Stoke Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for STOK and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:STOK) was last updated on 5/29/2025 by MarketBeat.com Staff
From Our Partners